AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02350855 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Improved Atta
Description: Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
Study NCT02350855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional counseling
Description: Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
Study NCT02350855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
Study NCT02350855 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity counseling
Description: Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
Study NCT02350855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
Study NCT04655742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaFlow™ Transcatheter Aortic Valve System
Description: VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
Study NCT03188536 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As it was an observational study, no intervention was administered in this study.
Study NCT02146729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Pedicle Screw Fixation
Description: Percutaneous Pedicle Screw Fixation
Study NCT02146729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Treatment
Description: Midline posterior incision with instrumentation.
Study NCT04052997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab Tesirine
Description: Intravenous Infusion
Study NCT00193596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
Study NCT00193596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV, days 1 and 8, in regimen B
Study NCT00193596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 1000 mg/m2 IV days 1 and 8 in regimen B
Study NCT00193596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 by 1-hour IV infusion, day 1, regimen A
Study NCT00193596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC) 6.0 IV, day 1, regimen A
Study NCT03935061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulberry juice
Description: On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
Study NCT03100136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PF-06809247
Description: PET Tracer
Study NCT03292497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment Algorithm
Description: Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle >=25 degrees, or repaired if the posterior leaflet tethering angle \<25 degrees.
Study NCT03292497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Treatment Algorithm
Description: Patients will have their valve repaired or replaced at the discretion of their surgeon.
Study NCT04377412 — intervention group
Intervention type: OTHER
Intervention: Pandemic control measures
Description: Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
Study NCT02710097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active inhaled cannabis
Description: \~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer.
Study NCT03246230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
Study NCT02710097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Study NCT02710097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Study NCT02710097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Oral Ethanol
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
Study NCT02710097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active cannabinoids. Administered over 20 minutes via a vaporizer.
Study NCT02710097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active cannabinoids. Administered over 20 minutes via a vaporizer.
Study NCT00723918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAB378
Description: SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
Study NCT00723918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
Study NCT00723918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
Study NCT00723918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAB placebo
Description: an inactive substance
Study NCT00723918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAB placebo
Description: an inactive substance
Study NCT00723918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone placebo
Description: Methadone placebo
Study NCT02024750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Resources
Description: Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
Study NCT01100918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiV ICD
Description: Biventricular ICD
Study NCT01100918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD
Description: Implantable Defibrillator
Study NCT02301364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib (BKM120)
Description: Buparlisib 100 mg once daily.
Study NCT01497340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Position at introitus level
Description: After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
Study NCT01497340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Position at Maternal Abdomen
Description: Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
Study NCT00887185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulator training for temporal bone surgery
Description: Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
Study NCT04579926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinpoint app
Description: Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
Study NCT02588573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (control)
Description: contact lens
Study NCT02588573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A (test)
Description: contact lens
Study NCT01341639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
Study NCT01341639 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INFANRIX™ hexa
Description: INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
Study NCT01341639 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq
Description: RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
Study NCT00887185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator training for temporal bone surgery
Description: Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
Study NCT01748123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
Study NCT01748123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
Study NCT01643798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
Study NCT01643798 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
Study NCT03772613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Administration of unfractionated heparin will be assessed using the activated clotting time
Study NCT01643798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS
Description: An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
Study NCT01643798 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Real rTMS
Description: An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
Study NCT02360202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impedance analysis
Description: Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.~impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle
Study NCT02360202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate cream treatment
Description: clobetasol propionate treatment initiated following French recommendations
Study NCT02666638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Volunteers
Description: MRI on up to a 7T scanner without contrast.
Study NCT02666638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Volunteers
Description: One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
Study NCT01053520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
Study NCT01053520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
Study NCT01053520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
Study NCT04092829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE
Description: The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
Study NCT03597022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befovacimab (BAY1093884)
Description: Once weekly doses until premature termination of the study, subcutaneous injection
Study NCT00223730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
Study NCT00223730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03061240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart pain assessment tool
Description: We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
Study NCT01635907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Study NCT02735096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EquiCue (Intraoral Electronic Balance Aid)
Description: When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
Study NCT02371564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow humidified oxygen
Study NCT02371564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard flow humidified oxygen
Study NCT03979183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumbopelvic, stretching, aerobic and relaxation exercises
Description: Intervention program will comprises brisk walks and small choreographies, global and analytical stretching exercises, as well as lumbopelvic stabilization exercises (with intensity and volume progression)
Study NCT03250585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exhaled Breath Condensate (EBC)
Description: Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
Study NCT03250585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Sample
Description: Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
Study NCT04959214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive relaxation egzersize
Description: Performing exercises in a quiet environment for 45 minutes with the Turkish Psychologists Association CD. Filling the PSQI and FSS before and 1 month after the application
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant Placebo
Description: Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (20 mg or 12 mg, PO) on Day 1
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (20 mg or 12 mg, PO) on Day 1
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron Placebo (PO, BID) on Days 2 and 3
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
Description: Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
Study NCT01636947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
Description: Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
Study NCT02706171 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Study NCT03968055 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Integration with Epic
Description: Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
Study NCT04312594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Patients were administered Jaktinib taken orally as tablets twice daily
Study NCT04312594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were administered Placebo taken orally as tablets twice daily
Study NCT02007044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02007044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02007044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02007044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04524585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade
Description: Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.
Study NCT03881059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986165 Placebo
Description: Participants will receive BMS-986165 matching placebo QD
Study NCT03881059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Dose A
Description: Participants will receive BMS-986165 Dose A QD.